StockwhizBeta
← Startup News
Funding round
Healthcare

Science Raises $400 million Series D to Accelerate PRIMA Availability and Prepare for US Launch

Stockwhiz
0 views
Science

Science has raised a $400 million Series D with participation from Khosla Ventures, the Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator and PLC Neurotech, among others. The capital will accelerate PRIMA’s availability across Europe, prepare for its United States launch and support infrastructure and biohybrid program investments.

At a Glance

Science

Healthcare
Raised
$400 million
Round
Series D
Investors
6
Investors
Khosla VenturesAckman Oxman InstituteTenet Healthcare885 CapitalY CombinatorPLC Neurotech
Target market
Patients blinded by certain types of late-stage macular degeneration
Use of funds
Accelerate PRIMA’s availability across Europe, prepare for its United States launch, expand research, manufacturing and operational infrastructure, and make substantial further investments in the biohybrid program

Key people

  • Max Hodak

    Co-Founder and CEO

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in

Quick Answers

What is the latest news about Science?

Science has raised a $400 million Series D with participation from Khosla Ventures, the Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator and PLC Neurotech, among others. The capital will accelerate PRIMA’s availability across Europe, prepare for its United States launch and support infrastructure and biohybrid program investments.

What does Science do?

Founded in 2021, Science develops neural interfaces, including PRIMA for patients blinded by certain types of late-stage macular degeneration and a biohybrid program combining engineered neurons with the brain’s circuits.

How much did Science raise?

Science raised $400 million in its Series D.

Who invested in Science?

Investors named in this Series D include Khosla Ventures, Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator and PLC Neurotech.

How will Science use the funding?

Science plans to use the money for accelerate PRIMA’s availability across Europe, prepare for its United States launch, expand research, manufacturing and operational infrastructure, and make substantial further investments in the biohybrid program.

Who are the key people at Science?

Key people named in this report: Max Hodak (Co-Founder and CEO).